Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Your cancer has been confirmed through a lab test (tissue sample) to be a specific type called Diffuse Large B-Cell Lymphoma (DLBCL)
- Your lymphoma has come back or stopped responding to previous treatment
- You are 18 years of age or older
- Your overall health and ability to care for yourself is significantly limited (confirm with trial site)
- If you are a woman, you are not breastfeeding, not pregnant, and agree to avoid pregnancy during the study and for 12 months after; if you are a man, you agree to ensure your partner does not become pregnant during the study and for 12 months after
- You have at least one measurable area of disease, such as a lymph node measuring 1.0 cm or larger, or a visible skin lesion that can be examined physically
- You are willing and able to sign a consent form agreeing to take part in the study
Who may not be able to join:
- Your lymphoma has spread into your bone marrow and makes up 25% or more of the cells there
- Your liver or kidney function test results are severely abnormal (more than 3 times higher than the normal range)
- You have an active infection that is not under control
- You have a heart condition with noticeable symptoms or significant problems with how your heart is working
- You currently have another type of cancer at the same time
- You have a psychological or mental health condition that would prevent you from taking part in the study or from signing a consent form
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Shuye Wang, PhD, First Affiliated Hospital of Harbin Medical University
Phone: 0451-85552320
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
A Prospective Study of Low-dose Decitabine Combined With COP Regimen in the Treatment of Relapsed and Refractory DLBCL
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.